Review Article

The Oxidative Function of Diferric Transferrin

Frederick L. Crane and Hans Löw

1 Department of Biological Science, Purdue University, West Lafayette, IN 47907, USA
2 Department of Molecular Medicine and Surgery, Karolinska Institute, 17177 Stockholm, Sweden

Correspondence should be addressed to Frederick L. Crane, flccoq10@aol.com

Received 2 October 2011; Accepted 9 November 2011

1. Introduction

The remarkable diversity of oxidative activity at the plasma membrane has only recently been brought into focus. Early study of peroxide generation in cells emphasized the role of mitochondria in relation to free radical generation [1, 2]. Other sources of \( \text{H}_2\text{O}_2 \) such as xanthine oxidase [3], monoamine oxidase [1], or disulfide bond formations [4] have been recognized, but attributed a lesser role. In the plasma membrane the controlled generation of \( \text{H}_2\text{O}_2 \) by leucocytes to fight infection is well established [5, 6]. More recently, the \( \text{H}_2\text{O}_2 \) generating capacity in plasma membrane of other types of cells has been recognized and proposed to be the basis for hormone and growth factor response, oxygen sensing [7], and microbicidal action [8–12]. These \( \text{H}_2\text{O}_2 \) generating systems have all been related to the NADPH oxidase GP91 phox Gp22 phox enzymes first recognized in neutrophils [5, 6]. Seven variations of this NADPH oxidase have been found and are designated as NOX1-5 and Duo NOX1-2 [9, 13]. The reaction with oxygen in all is catalyzed by the oxidation of low-potential cytochrome b 558. The members of the NOX groups are individually expressed in different tissues [9, 12]. Plasma membranes also have NADH oxidase activity [14–16]. Two forms of NADH oxidase have been extracted from plasma membranes and designated cNOX and tNOX [17]. These oxidases do not use cytochrome b558 as a terminal link to oxygen. The isolated enzyme also acts as a ubiquinol oxidase [18, 19] which may represent its physiological function in the plasma membrane. It could oxidize ubiquinol in the plasma membrane formed by reduction of ubiquinone from cytosolic NADH through NADH cytochrome b 5 reductase [20, 21]. The activation of the NADH oxidase by diferric transferrin and the relation to cellular control are the subjects of this paper.

2. Plasma Membrane Redox Systems

Plasma membranes isolated from rat liver or adipocytes have NADH oxygen oxidoreductase activity (NADH oxidase) [14, 21]. This oxidase activity is not inhibited by agents which inhibit NADH oxidase activity in mitochondria [15, 22] and is stimulated by diferric transferrin [23]. How this oxidase activity is related to other redox activity in plasma membrane remains to be established.

In addition to stimulation by diferric transferrin, the NADH oxidase of rat liver plasma membrane is stimulated by insulin and epidermal growth factor (EGF) [15]. Both
the endogenous NADH oxidase and the diferric transferrin-stimulated NADH oxidase are stimulated by coenzyme Q$_{10}$ and are inhibited by coenzyme Q analogs such as piericidin A [15, 21]. Thus, the diferric transferrin stimulated oxidase may require the reduced coenzyme Q oxidase (tNOX) [18, 24] and one of the known NADH dehydrogenases in the plasma membrane for the complete electron transfer chain from NADH to oxygen [19, 20, 25]. Diferric transferrin would be a terminal link to oxygen or can act to increase the reaction with oxygen. There are two NADH dehydrogenases which have been recognized in the plasma membrane. These are (A) the NADH cytochrome $b_5$ reductase [20] and (B) the NQ 0-1 (DT diaphorase) [26] which can oxidize both NADH and NADPH. Both of these NADH dehydrogenases can reduce coenzyme Q in the plasma membrane. The occurrence of these dehydrogenases may vary in different plasma membranes [20, 27]. In membranes where either one is present, they would be expected to function in any NADH oxidase system using coenzyme Q and reduced coenzyme Q oxidase to transfer electrons across the membrane. The transfer of electrons to oxygen in the unsupplemented plasma membrane can best be based on the activity of the reduced coenzyme Q oxidase [18]. At this time, the mechanism of reaction and the prosthetic groups involved are not known. There is also evidence for an iron site on the outer surface of the plasma membrane. This site is based on extraction of iron from the exterior of cells by the impermeable chelator bathophenanthroline disulfonate (BPS). Extraction of iron by BPS inhibits ferricyanide reduction outside the cell, but it is not known if the extraction inhibits oxidase activity [28]. An additional enzyme in plasma membrane which can act as an NADH dehydrogenase is the VDAC pore complex. This enzyme catalyzed NADH ferricyanide reductase activity, but it is not known if it can act as an oxidase or contribute to NADH oxidase activity [25].

3. Evidence for Diferric Transferrin As an Electron Acceptor

The stimulation of the plasma membrane NADH oxidase activity by diferric transferrin opens the possibility for a more efficient terminal link to oxygen. There is good evidence that the Fe$_2$:Tf can act as a terminal oxidase with liver plasma membrane. Two methods have been used to show that diferric transferrin can be reduced by NADH at the plasma membrane [23]. One is by direct measure of the decrease in absorbance of the diferric transferrin at 465 nm when diferric transferrin is in the presence of NADH and isolated plasma membrane. The reduction occurs only in absence of air, and the diferric transferrin absorbance returns immediately when air is admitted [29]. This shows that NADH and plasma membrane can reduce the iron in diferric transferrin anaerobically and that the iron is rapidly reoxidized in the presence of oxygen [23]. The absorbance at 465 nm is characteristic of diferric transferrin [30]. The second assay for reduction of diferric transferrin by NADH and plasma membrane measures the formation of ferrous bathophenanthroline disulfonate (BPS) at 535 nm [23]. This procedure has also been used to show diferric transferrin reduction at the surface of several different types of cells [31–34]. The use of BPS to show the reduction of iron in diferric transferrin has been objected to on the basis that BPS effectively raises the redox potential of the ferric transferrin so that it can be reduced by NADH [35]. This is true since the BPS would stabilize the ferrous iron and prevent its reoxidation to ferric by rebinding to the transferrin. The BPS effect would be similar to keeping the iron under anaerobic conditions. The assay does show that electrons from NADH can cross the plasma membrane to reduce the iron in diferric transferrin. Under aerobic conditions without the chelator the ferrous iron would be immediately reoxidized by oxygen to recombine with transferrin and therefore would not be available for transport into the cell as ferrous iron. Thorstensen and Romslo [36] have made an extensive analysis of the relation of the redox system and iron uptake and conclude that at least for hepatocytes the redox system appears to contribute to iron uptake. They point out that anaerobic conditions favor iron uptake by liver cells which is consistent with the effect of argon on the rate of formation of ferrous BPS by liver or HeLa cells incubated with diferric transferrin [37, 38]. Argon increases the rate of ferrous BPS formation by 59% with HeLa cells and by 25% with liver cells. The reduction of ferric ammonium citrate (FAC) is not stimulated under argon [38] which is consistent with much slower reoxidation of ferrous iron not associated with transferrin. The assay of NADH oxidation in the presence of diferric transferrin and plasma membrane provides a corollary to the direct assays of diferric transferrin reduction. The rate of NADH oxidation is increased by addition of diferric transferrin to the plasma membrane. This is consistent with a rapid transfer of electrons to oxygen through diferric transferrin reduction and reoxidation. The stimulation is quite specific for NADH oxidation. With rat liver plasma membranes, diferric transferrin stimulated NADH oxidase 60% and NADPH oxidase 14% [15, 23]. The stimulation was inhibited by the GB16 antibody to the transferrin receptor [39], but increased transferrin receptor in tumor cells does not necessarily increase stimulation [40] which indicates that the transferrin receptor itself is not alone sufficient to act as an oxidase. Diferric lactoferrin is not involved in iron uptake, but is effective in stimulation of cell growth [41, 42]. Diferric lactoferrin also stimulates rat liver plasma membrane NADH oxidase. In a preparation where diferric transferrin stimulated NADH oxidase 73% diferric lactoferrin stimulated 80%. For both, the stimulation is inhibited by the transferrin or lactoferrin antibody [33], respectively. Assay with isolated plasma membrane does not show orientation of the enzyme, so the oxidation of internal NADH was measured using whole cells.

4. Evidence for a Transmembrane Oxidase

The transmembrane nature of the transferrin-stimulated oxidase can be demonstrated by measuring the cellular concentration of NADH. The oxidation of NAD(P)H in intact K562 cells is seen in the decrease of absorbance at 340 nm when diferric transferrin is added to the cells [34]. This shows that the reduced pyridine nucleotides are oxidized. By
using a specific enzymatic assay for NADH, the decrease in HeLa cells on addition of diferric transferrin has been shown [43, 44]. The evidence that addition of diferric transferrin to cells stimulates the immediate oxidation of internal NADH indicating that reduction and reoxidation of diferric transferrin on the outside of cells can catalyse oxidation of internal NADH. Inhibition of the transferrin stimulated NADH oxidase by inhibitors of the coenzyme Q pathway is further evidence that the coenzyme Q requiring NADH oxidase is the major site of stimulation during transferrin stimulation. Capsaicin inhibits diferric transferrin reductase 88% [21], whereas the transmembrane electron transport in neutrophils is not inhibited by the capsaicin analog resiferatoxin [45]. The coenzyme Q analog piericidin also inhibits rat liver plasma membrane transferrin stimulated NADH oxidase, and the inhibition is partially reversed by coenzyme Q [46].

5. The Redox System Involved in Transferrin Reduction

With liver plasma membrane, addition of Fe$_2$Tf increases oxidation of both NADH and NADPH. The increase is greater during oxidation of NADH compared to NADPH [15, 23]. There is evidence that oxygen is the terminal acceptor since there is no net reduction of ferric transferrin under aerobic conditions. NADPH has not been tested as an electron donor under anaerobic conditions. Also unknown is which of the transplasma membrane oxidase systems is responsible for the transferrin stimulated oxidation. With liver plasma membrane the dehydrogenase involved is apparently one of the enzymes which requires coenzyme Q as shown by reversible decrease in activity after extraction of CoQ. This would involve either the NADH cyt b$_5$ reductase or the NADH/NADPH DT diaphorase [26]. There is a report that VDAC-1 can also act as a NADH CoQ reductase so that it is not excluded from a role in transferrin stimulated oxidase [25]. Since there is no evidence that the NADPH oxidase of the NOX1-5 series requires coenzyme Q it is unlikely that they function as the primary transferrin reductase in liver membranes. However it is possible that they transfer electrons through the low-potential cyt b$_{558}$ to diferric transferrin. Also, it should be noted that not all of the Fe$_2$Tf-stimulated oxidase was lost after CoQ extraction. The residual activity could be based on NOX-3 which has been identified in liver [47]. The components of the transferrin stimulated NADH oxidase are shown in Figure 1.

6. Adventitious Oxidase

In studies before 1988, we found considerable variation in the rate of diferric transferrin reduction with different preparations of diferric transferrin. Measurement of adventitious loosely bound iron using ascorbate as a reductant and BPS to measure formation of ferrous BPS showed that the most active preparations contained up to 1 u mole of loosely bound iron [37] per u mole transferrin. After 1988, diferric transferrin was checked for adventitious iron [31, 33, 37]. All the assay procedures done after 1988 with diferric transferrin tested for adventitious iron show significant reduction of the diferric transferrin or stimulation of NADH oxidase although the rates are clearly higher if extra iron is present. This is consistent with the stimulation of reduction when ferric ammonium citrate is added along with transferrin as shown in Table 2 [31]. An involvement of the transferrin receptor in activation of the iron reduction may be indicated since the rate with transferrin present can increase over the rate with the same amount of iron [31].

The direct spectrophotometric assay of diferric transferrin reduction by NADH with liver plasma membrane would not be influenced by adventitious iron [23]. The inhibition of diferric transferrin reduction by apotransferrin may also be attributed partly to binding of adventitious iron to the apotransferrin, since apotransferrin does not always bind strongly to the transferrin receptor [54]. The stimulation of plasma membrane NADH oxidation by different preparations of diferric transferrin is shown in Table 1. The amount of adventitious iron was not measured before 1988 so the higher rates probably reflect the presence of excess iron. After 1988, the diferric transferrin was tested for extra iron by the ascorbate reduction test.

These preparations show a more consistent low rate of stimulation. The effect of NAD(P)H oxidase stimulation by diferric transferrin (without extra iron) can be demonstrated by direct spectrophotometric measurement of decrease of NAD(P)H in K562 cells at 340 nm when diferric transferrin is added to the cells [34].

7. Function of the Oxidase

The overall effects of diferric transferrin stimulation of the plasma membrane NADH oxidase may be encountered both inside and outside the cells. Inside the oxidation, stimulation can shift the redox poise of the cell by oxidation of the reduced pyridine nucleotide [34] and increase NAD concentration. Outside, transferrin may introduce an
Table 1: Stimulation of NADH oxidase of rat liver plasma membrane by diferric transferrin (Fe₂Tf) with control of adventious iron in the Fe₂Tf.

| Year of publication | Fe₂Tf Concentration | Extra Fe | NADH oxidase Stimulation n mole min⁻¹ 1 mg protein⁻¹ | References |
|---------------------|---------------------|----------|-----------------------------------------------|------------|
| 1986                | 3.4                 | ?        | 3.0                                           | [31]       |
| 1987                | 3.4                 | ?        | 2.6 ± 0.3                                     | [49]       |
| 1987                | 10                  | ?        | 7.4 ± 0.2                                     | [44]       |
| 1987                | 17                  | ?        | 17                                            | [42]       |
| 1990                | 3.5                 | ?        | 5.4                                           | [50]       |
| 1990                | 10                  | NO       | 0.77 ± 0.07                                   | [51]       |
| 1991                | 3                   | NO       | 0.9                                           | [8]        |
| 1991                | 10                  | NO       | 0.5                                           | [23]       |
| 1991                | 17                  | NO       | 1.1                                           | [52]       |
| 1992                | 3.4                 | NO       | 2.0                                           | [26]       |
| 1992                | 17                  | NO       | 4.5                                           | [26]       |
| 1992                | 12.5                | NO       | 0.91                                          | [53]       |

Table 2: Effect of diferric transferrin on the rate of iron reduction with ferric ammonium citrate (FAC) by SV40/ST3 cells. Assay with diferric transferrin Fe₂Tf tested for presence of adventious iron. Data from reference [31].

| Micromolar additions | Rate of iron reduction (FeBPS formation) n mole mm⁻² cells × 10⁻⁶ |
|----------------------|---------------------------------------------------------------|
| FAC 7.5              | 0.4                                                          |
| Fe₂Tf 28             | 0.6                                                          |
| FAC + Fe₂Tf          | 1.9                                                          |

alternative source of superoxide by one-electron transfer from ferrous iron to oxygen. Oxidation of NADH by the endogenous oxidase in absence of transferrin is reported not to generate superoxide [24, 55]. A low level of hydrogen peroxide generation by NADH oxidation with liver plasma membranes has been observed [56], but the rate of H₂O₂ production was only 3 percent of the rate of oxygen uptake with NADH. The rate of NADPH oxidation which could be a measure of NOX activity was less than 10 percent of the NADH, oxidase but was associated with 50 percent H₂O₂ production.

Superoxide production from NADH at the cell surface can be stimulated by ultraviolet light [57] or phenazine methosulfate [45]. The effect of diferric transferrin on superoxide production at the surface of cells needs to be determined.

Stimulation of the oxidase or transfer of electrons through transferrin iron may increase surface superoxide production above any production by the endogenous oxidase in absence of diferric transferrin.

A further important function activated by the diferric transferrin is the release of protons from the cells either in conjunction with electron transport or by stimulation of the Na⁺/H⁺antiport. Part of the stimulated proton release is inhibited by amiloride inhibitors of the antiport, and a small part is not inhibited and is stoichiometric to electron transport [33, 50, 58]. Activation of the antiport increases the internal pH and increases membrane potential [38]. The oxidase also controls the concentration of cytosolic NAD which can activate sirtuin that controls metabolic functions [59, 60].

The transferrin stimulated transplasma membrane NADH oxidase may also be involved in control of reactive oxygen species generated in hyperglycaemia or with excess ethanol. Although there are multiple mechanisms involved in hyperglycaemic damage, one aspect is the generation of reactive oxygen species from glycolytic NADH [61]. The major source of ROS based on high glucose in both adipocytes and endothelial cells is mitochondrial pyruvate as indicated by inhibitors. NADH generated by glycolysis in the cytosol did not contribute which suggests that cytosolic NADH is oxidized by the plasma membrane oxidase without generation of ROS [59]. The presence of copper in the oxidase would be consistent with a complete reduction of oxygen to water [48].

On the other hand, in adipocytes, Wu et al. [11] show that the NADH/NADPH oxidase inhibitor diphenyleneiodonium strongly inhibits glucose-stimulated ROS production which suggests inhibition of the plasma membrane oxidase decreases glucose-stimulated ROS generation. With excess ethanol, cells with alcohol dehydrogenase would produce excess cytosolic NADH which would be available for oxidation by the plasma membrane oxidase. Diferric transferrin would increase the oxidation of cytosolic NADH [43] which would lead to formation of ROS if the ferrous iron is reoxidized by a one-electron transfer to oxygen. Thus, the extent of diferric stimulation of the oxidase may influence the damaging effects of excess ethanol. Cells respond to hypoxia by preventing the prolyl hydroxylase-catalyzed breakdown of the transcription factor HIF-1α [49]. The diferric transferrin stimulated NADH oxidase may influence the response to mild hypoxia. Generation of ROS decreases ferrous iron to decrease the activity of prolylhydroxylase to decrease the breakdown of HIF-1α which would increase the response to mild hypoxia [53] by preserving HIF-1α. Oxidation of cytosolic NADH by the plasma membrane oxidase should decrease mitochondrial generation of cytosolic ROS to allow...
increased HIF-1α breakdown. Inhibition of the plasma membrane oxidase should decrease loss of HIF-1α. Influence on the level of HIF-1α can be important in vital gene regulation and tumor control [52].

Effects on redox state may be enhanced if extra iron is present in the form of ferric citrate since it is clear that extra iron in addition to the two tightly bound atoms in diferric transferrin can further stimulate the plasma membrane oxidase.

Two questions remain unanswered. (A) Does reoxidation of the reduced iron during rebinding to transferrin produce superoxide? and (B) how do functions activated by the transfer of electrons to transferrin affect cell growth or survival [62] and is transferrin stimulation of cell growth based, at least in part, on stimulation of the plasma membrane NADH oxidase?

8. Conclusions

Plasma membrane NADPH oxidases are clearly important to plasma membrane signal transduction. Since the plasma membrane NADH oxidase also responds to growth factors like EGF, it may also have a role in signaling. The diferric transferrin stimulation of the NADH oxidase got lost in the discussion of its possible relation to iron uptake. The relation of this transferrin stimulation to the growth stimulation by transferrin remains to be examined. It is likely to play a unique role since ferric lactoferrin which does not participate in iron uptake has also been effective in growth stimulation and in NADH oxidase stimulation. The ferric transferrin stimulation of the oxidase also decreases cytosolic NADH and stimulates the Na+/H+ antiport which can relate to signal transduction in addition to possible superoxide generation based on the reoxidation of the transferrin iron. The action of excess iron associated with transferrin in further stimulation of the oxidase may relate to problems of iron overload.

Abbreviations

BPS: Bathophenanthroline disulfonate  
CoQ10: Coenzyme Q with a 10 isoprene unit side chain  
FAC: Ferric ammonium citrate  
Fe₂Tf: Diferric transferrin  
cNOX: NADH oxidase bound tightly to membrane  
tNOX: NADH oxidase weakly bound to membrane  
EGF: Epidermal growth factor  
VDAK: Voltage-dependent anion channel  
HIF-1α: Hypoxia-induced transcription factor.

Acknowledgments

The authors thank Ms. Melanie K. Davis for assistance in preparation of the paper, and Mr. Eric J. Teske for technical assistance.

References

[1] E. Cadenas and K. J. A. Davies, “Mitochondrial free radical generation, oxidative stress, and aging,” Free Radical Biology & Medicine, vol. 29, no. 3-4, pp. 222–230, 2000.
[2] H. Nohl, K. Staniek, A. V. Kozlov, and L. Gille, “The biomolecule ubiquinone exerts a variety of biological functions,” Biofactors, vol. 18, no. 1-4, pp. 23–31, 2003.
[3] S. G. Rhee, “Redox signaling: hydrogen peroxide as intracellular messenger,” Experimental and Molecular Medicine, vol. 31, no. 2, pp. 53–59, 1999.
[4] B. P. Tu and J. S. Weissman, “Oxidative protein folding in eukaryotes: mechanisms and consequences,” The Journal of Cell Biology, vol. 164, no. 3, pp. 341–346, 2004.
[5] A. R. Cross and A. W. Segal, “The NADPH oxidase of professional phagocytes: Prototype of the NOX electron transport chain systems,” Biochimica et Biophysica Acta, vol. 1657, no. 1, pp. 1–22, 2004.
[6] A. W. Segal and K. P. Shatwell, “The NADPH oxidase of phagocytic leukocytes,” Annals of the New York Academy of Sciences, vol. 832, pp. 215–222, 1997.
[7] J. K. Maranchie and Y. Zhan, “NQO1 is critical for hypoxia-inducible factor 2-α transcriptional activity in von Hippe1-Lindau-deficient renal cell carcinoma,” Cancer Research, vol. 65, no. 20, pp. 9190–9193, 2005.
[8] R. Meier, “Superoxide generation of phagocytes and nonphagocytic cells,” Protoplasma, vol. 217, no. 1–3, pp. 117–124, 2001.
[9] K. K. Griendling, “NADPH oxidases: new regulators of old functions,” Antioxidants & Redox Signaling, vol. 8, no. 9–10, pp. 1443–1445, 2006.
[10] M. Geiszt and T. Leto, “The Nox family of NAD(P)H oxidases: host defense and beyond,” The Journal of Biological Chemistry, vol. 272, pp. 217–221, 1997.
[11] X. Wu, L. Zhu, A. Zilbering et al., “Hyperglycemia potentiates H2O2 production in adipocytes and enhanced insulin signal transduction,” Antioxidants & Redox Signaling, vol. 7, no. 5–6, pp. 526–537, 2005.
[12] G. L. Leto and T. L. Geiszt, “Role of NAD(P)H oxidases in host defense,” Antioxidants & Redox Signaling, vol. 8, no. 9–10, pp. 1549–1561, 2006.
[13] M. Geiszt, J. Witta, J. Baffi, K. Lekstrom, and T. L. Leto, “Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense,” The FASEB journal, vol. 17, no. 11, pp. 1502–1504, 2003.
[14] F. L. Crane and H. Low, “NADH oxidation in liver and fat cell plasma membranes,” FEBS Letters, vol. 68, no. 2, pp. 153–156, 1976.
[15] A. O. Brightman, R. K. M. Miu, I. L. Sun, R. Barr, F. L. Crane, and D. J. Morre, “A growth factor- and hormone-stimulated NADH oxidase from rat liver plasma membranes,” Biochimica et Biophysica Acta, vol. 1105, no. 1, pp. 109–117, 1992.
[16] J. M. Merker, R. D. Bongard, N. J. Kettenhofen, Y. Okamoto, and C. A. Dawson, “Intracellular redox state affects transplasma membrane electron transport in pulmonary arterial endothelial cells,” American Journal of Physiology, vol. 282, no. 1, pp. L36–L43, 2002.
[17] D. J. Morré and D. M. Morré, “Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases,” Free Radical Research, vol. 37, no. 8, pp. 795–808, 2003.
[18] T. Kishi, D. M. Morre, and D. J. Morre, “The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity,” Biochimica et Biophysica Acta, vol. 1412, pp. 66–77, 1999.
[19] T. Kishi, T. Takahashi, A. Usui, N. Hashizume, and T. Okamoto, “Cytosolic NADPH-UQ reductase, the enzyme
responsible for cellular ubiquinone redox cycle as an endogenous antioxidant in the rat liver,” *BioFactors*, vol. 9, no. 2–4, pp. 189–197, 1999.

[20] F. Navarro, J. M. Villaalba, F. L. Crane, W. C. Mackellar, and P. Navas, “A phospholipid-dependent NADH-coenzyme Q reductase from liver plasma membrane,” *Biochemical and Biophysical Research Communications*, vol. 212, no. 1, pp. 138–143, 1995.

[21] I. L. Sun, E. E. Sun, F. L. Crane, D. J. Morre, A. Lindgren, and H. Low, “Requirement for coenzyme Q in plasma membrane electron transport,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 23, pp. 11126–11130, 1992.

[22] D. P. Gayda, F. L. Crane, D. J. Morre, and H. Low, “Hormone effects on NADH-oxidizing enzymes of plasma membranes of rat liver,” *Proceedings of the Indiana Academy of Science*, vol. 86, pp. 385–390, 1977.

[23] I. L. Sun, P. Navas, F. L. Crane, D. J. Morre, and H. Löw, “NADH diferric transferrin reductase in liver plasma membrane,” *The Journal of Biological Chemistry*, vol. 262, no. 33, pp. 15915–15921, 1987.

[24] J. Morre, “NADH oxida: a multifunctional ectoprotein of the eukaryotic cell surface,” in *Plasma Membrane Redox Systems*, H. Asard, A. Berczi, and R. J. Carrbergs, Eds., pp. 121–126, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998.

[25] M. A. Baker, D. J. R. Lane, J. D. Ly, V. De Pinto, and A. Lawen, “Voltage dependent anion channel 1 is a NADH ferricyanide reductase,” *The Journal of Biological Chemistry*, vol. 279, no. 6, pp. 4811–4819, 2004.

[26] R. E. Beyer, J. Segura-Aguilar, S. Di Bernardo et al., “The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (Reduced) form of coenzyme Q in membranes,” *Molecular Aspects of Medicine*, vol. 18, pp. S15–S23, 1997.

[27] R. De Cabo, R. Cabello, M. Rios et al., “Calorie restriction attenuates age-related alterations in the plasma membrane antioxidant system in rat liver,” *Experimental Gerontology*, vol. 39, no. 3, pp. 297–304, 2004.

[28] F. J. Alcain, H. Löw, and F. L. Crane, “Iron reverses impermeable chelator inhibition of DNA synthesis in CCI 39 cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 17, pp. 7903–7906, 1994.

[29] G. W. Bates, E. F. Workman, and M. R. Schlabach, “Oxidation of ferrous iron by transferrin in air,” *Biochemical and Biophysical Research Communications*, vol. 50, pp. 84–90, 1973.

[30] D. M. Surgenor, B. A. Koechlin, and L. E. Strong, “The properties of ferric transferrin,” *The Journal of Clinical Investigation*, vol. 28, pp. 73–85, 1949.

[31] H. Low, F. L. Crane, C. Grebing, M. Isaksson, A. Lindgren, and I. L. Sun, “Modification of transferran plasma membrane oxidoreduction by SV40 transformation of 3T3 cells,” *Journal of Bioenergetics and Biomembranes*, vol. 23, no. 6, pp. 903–917, 1991.

[32] H. Low, I. L. Sun, and P. Navas, “Transplasmalemma electron transport from cells in part of a diferric transferrin reductase system,” *Biochemical and Biophysical Research Communications*, vol. 139, no. 3, pp. 1117–1123, 1986.

[33] I. L. Sun, F. L. Crane, D. J. Morre, H. Low, and W. P. Faulk, “Lactoferrin activates plasma membrane oxidase and Na+/H+ antiport activity.” *Biochemical and Biophysical Research Communications*, vol. 176, no. 1, pp. 498–504, 1991.

[34] W. Page Faulk, K. Barabas, I. L. Sun, and F. L. Crane, “Transferrin-adiamycin conjugates which inhibit tumor cell proliferation without interaction with DNA inhibit plasma membrane oxidoreductase and proton release in K562 cells,” *Biochemistry International*, vol. 25, no. 5, pp. 815–822, 1991.

[35] K. Thorstensen and P. Aisen, “Release of iron from diferric transferrin in the presence of rat liver plasma membranes: no evidence of a plasma membrane diferric transferrin reductase,” *Biochimica et Biophysica Acta*, vol. 1052, no. 1, pp. 29–35, 1990.

[36] K. Thorstensen and I. Romso, “The role of transferrin in the mechanism of cellular iron uptake,” *Biochemical Journal*, vol. 271, no. 1, pp. 1–10, 1990.

[37] H. Low, A. Lindgren, F. L. Crane, I. L. Sun, W. Toole-Simms, and D. J. Morre, “Transplasma membrane electron transport function as a ferric reductase,” in *Plasma Membrane Oxidoreductases in Control of Animal and Plant Growth*, F. L. Crane, D. J. Morre, and H. Low, Eds., pp. 153–161, Plenum, New York, NY, USA, 1988.

[38] F. L. Crane, H. Low, I. L. Sun, D. J. Morre, and W. P. Faulk, “Interaction between oxidoreductase, transferrin receptor and channels in plasma membrane,” in *Growth Factors from Genes to Clinical Applications*, V. R. Sara, K. Hall, and H. Low, Eds., pp. 129–139, Raven, New York, NY, USA, 1990.

[39] W. Toole-Simms, I. L. Sun, W. P. Faulk et al., “Inhibition of transplasma membrane electron transport by monoclonal antibodies to the transferrin receptor,” *Biochemical and Biophysical Research Communications*, vol. 176, no. 3, pp. 1437–1442, 1991.

[40] D. J. Morre, F. L. Crane, L. C. Eriksson, H. Low, and D. M. Morre, “NADH oxidae of liver plasma membrane stimulated by diferric transferrin and neoplastic transformation induced by the carcinogen 2-acetylaminofluorene,” *Biochimica et Biophysica Acta*, vol. 1057, no. 1, pp. 140–146, 1991.

[41] R. Oria, X. Alvarez-Hernández, J. Liceaga, and J. H. Brock, “Uptake and handling of iron from transferrin, lactoferrin and immune complexes by a macrophage cell line,” *Biochemical Journal*, vol. 252, no. 1, pp. 221–225, 1988.

[42] D. Roiron-Lagroux and C. Figarella, “Evidence for a different mechanism of lactoferrin and transferrin translocation on HT 29-D4 cells,” *Biochemical and Biophysical Research Communications*, vol. 170, no. 2, pp. 837–842, 1990.

[43] P. Navas, I. L. Sun, D. J. Morre, and F. L. Crane, “Decrease of NADH in HeLa cells in the presence of transferrin or ferricyanide,” *Biochemical and Biophysical Research Communications*, vol. 135, no. 1, pp. 110–115, 1986.

[44] I. L. Sun and F. L. Crane, “Control of transplasma membrane diferric transferrin reductase by anti tumor drugs,” in *Plasma Membrane Oxidoreductases in Control of Animal and Plant Growth*, F. L. Crane, D. J. Morre, and H. Low, Eds., pp. 181–190, Plenum, New York, NY, USA, 1988.

[45] M. V. Berridge and A. S. Tan, “NADH oxidase of liver plasma membrane stimulated by diferric transferrin and neoplastic transformation induced by the sulfonated tetrazolium salt WST-1,” *Protoplasma*, vol. 190, no. 1–4, pp. 74–82, 1998.

[46] F. L. Crane, I. L. Sun, E. S. Sun, and D. J. Morre, “Alternative functions for coenzyme Q in endomembranes,” in *Biomedical and Clinical Aspects of Coenzyme Q*, K. Follers, G. P. Littarru, and T. Yamagami, Eds., pp. 59–70, Elsevier, Amsterdam, The Netherlands, 1991.

[47] G. Cheng, Z. Cao, X. Xu, E. G. V. Meir, and J. D. Lambeth, “Homologs of gp91phox: cloning and tissue expression of
Nox3, Nox4, and Nox5,” *Gene*, vol. 269, no. 1-2, pp. 131–140, 2001.

[48] X. Tang, P. J. Chueh, Z. Jiang et al., “Essential role of copper in the activity and regular periodicity of a recombinant, tumor-associated, cell surface, growth-related and time-keeping hydroquinone (NADH) oxidase with protein disulfide-thiol interchange activity (ENOX2),” *Journal of Bioenergetics and Biomembranes*, vol. 42, no. 5, pp. 355–360, 2010.

[49] M. Safran and W. G. Kaelin Jr., “HIF hydroxylation and the mammalian oxygen-sensing pathway,” *The Journal of Clinical Investigation*, vol. 111, no. 6, pp. 779–783, 2003.

[50] I. L. Sun, R. Garcia-Canero, and W. Liu, “Diferric transferrin reduction stimulates the Na+/H+ antiport of HeLa cells,” *Biochemical and Biophysical Research Communications*, vol. 145, no. 1, pp. 467–473, 1987.

[51] I. L. Sun, P. Navas, F. L. Crane, D. J. Morre, and H. Low, “Diferric transferrin reductae in the plasma membrane is inhibited by adriamycin,” *Biochemistry International*, vol. 14, pp. 119–127, 1987.

[52] J. Pouyssegur, F. Dayan, and N. M. Maze, “Hypoxia signalling in cancer and approaches to enforce tumour regression,” *Nature*, vol. 441, no. 7092, pp. 437–443, 2006.

[53] E. Berra, A. Ginouvès, and J. Pouyssegur, “The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling,” *EMBO Reports*, vol. 7, no. 1, pp. 41–45, 2006.

[54] H. Löw, C. Grebing, A. Lindgren, M. Tally, I. L. Sun, and F. L. Crane, “Involvement of transferrin in the reduction of iron by the transplasma membrane electron transport system,” *Journal of Bioenergetics and Biomembranes*, vol. 19, no. 5, pp. 535–549, 1987.

[55] D. J. Morre and F. L. Crane, “NADH oxidase,” in *Oxidoreduction at the Plasma Membrane Relation to Growth and Transport*, F. L. Crane, D. J. Morre, and H. Low, Eds., vol. 1, pp. 67–84, CRC Press, Boca Raton, Fla, USA, 1990.

[56] T. Ramasarma, A. Swaroop, W. MacKellar, and F. L. Crane, “Generation of hydrogen peroxide on oxidation of NADH by hepatic plasma membranes,” *Journal of Bioenergetics and Biomembranes*, vol. 13, no. 5-6, pp. 241–253, 1981.

[57] D. J. Morré, R. Pogue, and D. M. Morré, “A multifunctional hydroquinone oxidase of the external cell surface and sera,” *BioFactors*, vol. 9, no. 2-4, pp. 179–187, 1999.

[58] E. Sun, J. Lawrence, D. M. Morre et al., "Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984)," *Biochemical Pharmacology*, vol. 50, no. 9, pp. 1461–1468, 1995.

[59] T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” *Nature*, vol. 404, no. 6779, pp. 787–790, 2000.

[60] D. McGuinness, D. H. McGuinness, J. A. McCaul, and P. G. Shiels, “Sirtuins, bioageing, and cancer,” *Journal of Aging Research*, vol. 2011, Article ID 235754, 11 pages, 2011.

[61] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” *Nature*, vol. 414, no. 6865, pp. 813–820, 2001.

[62] A. D. N. J. Grey, “Biomedical aspects of plasma membrane redox,” *Antioxidants & Redox Signaling*, vol. 2, no. 2, pp. 155–156, 2000.